Roche Holding AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- Neoplasms
- Interventions
- Drug: RG1507Drug: RO1507Drug: erlotinib [Tarceva]Drug: bevacizumab [Avastin]Drug: pemetrexelDrug: carboplatinDrug: capecitabine [Xeloda]Drug: sorafenibDrug: temozolomideDrug: cetuximabDrug: paclitaxelDrug: etoposideDrug: mFOLFOX6Drug: trastuzumab [Herceptin]Drug: docetaxelDrug: gemcitabineDrug: irinotecan
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 104
- Registration Number
- NCT00811993
A Study of Taspoglutide in Type 2 Diabetic Patients
- First Posted Date
- 2008-12-19
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 18
- Registration Number
- NCT00811460
A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab) and Xeloda (Capecitabine) in Patients With HER2-Positive Breast Cancer
Phase 2
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2016-09-29
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT00811135
A Study of Tocilizumab in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Current Non-Biologic DMARDs
- First Posted Date
- 2008-12-18
- Last Posted Date
- 2017-08-03
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 14
- Registration Number
- NCT00810277
- Locations
- 🇫🇮
Kanta-Hämeen Keskussairaala ; Reumatologia, Hämeenlinna, Finland
🇫🇮Kiljavan Lääketutkimus Oy, Hyvinkää, Finland
🇫🇮Kanta-Hämeen keskussairaala; Riihimäen aluesairaala Reumapoliklinikka, Riihimäki, Finland
A Study of RO4917523 in Patients With Treatment Resistant Depression
Phase 2
Completed
- Conditions
- Depression
- Interventions
- Drug: RO4917523Drug: Placebo
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 46
- Registration Number
- NCT00809562
A Study of the Effect of Taspoglutide on Gastric Emptying in Patients With Type 2 Diabetes
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 60
- Registration Number
- NCT00809705
A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2008-12-17
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 556
- Registration Number
- NCT00810199
A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Phase 3
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-12-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1044
- Registration Number
- NCT00806923
A Study of Combination Treatment With an HCV Polymerase Inhibitor (RO5024048) and an HCV Protease Inhibitor (RO5190591/Danoprevir) in Genotype 1 Chronic Hepatitis C Patients
- First Posted Date
- 2008-12-03
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 88
- Registration Number
- NCT00801255
A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols
Phase 3
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Pegylated-interferon alfa-2aDrug: Ribavirin
- First Posted Date
- 2008-12-02
- Last Posted Date
- 2013-10-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT00800735
© Copyright 2025. All Rights Reserved by MedPath